HIMS vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HIMS demonstrates strong operational health with a Piotroski F-Score of 7/9, signaling robust financial trends and efficiency. However, the stock is severely overvalued from a deterministic standpoint, trading at $29.39 against a Graham Number of $5.23 and an Intrinsic Value of $3.57. While revenue growth is strong (28.4%) and gross margins are impressive (73.83%), the valuation premium is extreme. This, combined with bearish insider selling and a negative technical trend, offsets the company's fundamental operational strengths.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
HIMS vs MRK: Head-to-Head Comparison
This page compares Hims & Hers Health, Inc. (HIMS) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.